DICE Therapeutics
Dimitri Fillos has a diverse work experience that spans over two decades. Their most recent position is as the Director of Vendor & Operations Management at DICE Therapeutics, where they started in October 2021. Prior to that, they had a long tenure at Genentech, starting in 2011. At Genentech, they held the role of Global Strategic Alliance Lead from June 2017 to October 2021 and also served as a Project Manager for Sample Operations from March 2011 to June 2017. Before their time at Genentech, Dimitri worked as a Senior Associate Health Scientist at ChemRisk from June 2008 to March 2011. Dimitri also worked as a Senior Research Specialist at Emory University from August 2004 to May 2008, and as a Sales Representative at Aero Pharmaceuticals Inc. from January 2004 to August 2004. Dimitri's career began at the Centers for Disease Control and Prevention, where they worked as a Research Biologist from July 2001 to January 2004.
Dimitri Fillos completed their Bachelor of Science degree in Biology from The University of Georgia from 1997 to 2000. Dimitri then pursued further education and obtained a Master of Public Health degree with a focus on Epidemiology from Emory University between 2005 and 2008.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.